title: MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.
abstract: Approximately 35% of breast cancers exhibit PIK3CA activating mutation. Since PIK3CA hotspot mutation is the most frequently mutated gene in human breast cancers and primarily overlaps in HER2+ as well as ER+ breast cancers, the subset of patients bearing PIK3CA activating mutation does not get fullest benefit from either anti-HER2 or anti-hormonal agents. Literature also suggests that these patients may have chemotherapy resistance. Indeed, multiple clinical trials are currently evaluating the efficacy of over 30 drugs targeting different nodal points in the PI3K-AKT-mTOR pathway in breast and other cancers. However, to date, responses of solid tumors to PI3K pathway inhibitor monotherapy remains modest with an accompanied rapid emergences of drug resistance. MYC elevation represents one of the potential modes of actions by which breast tumors develop resistance to the PI3K pathway-specific targeted therapies. As products of oncogenes, both MYC and PIK3CA are well-established onco-proteins which contribute to breast oncogenesis. However, their similarities out number their dissimilarities in the context of their specific oncogenic cellular signals. In this review we will describe the specific cellular signals initiated following alteration in the MYC gene and PIK3CA gene in breast cancers. We will interrogate how MYC gene alterations influence the action of PI3K pathway targeted drugs in the context of PIK3CA mutation towards the development PI3K inhibitor induced drug-resistance in breast cancers.
authors: Department of Molecular & Experimental Medicine, Avera Research Institute Sioux Falls, SD ; Department of Internal Medicine, SSOM, University of South Dakota SD.
authors: Nandini
authors: N
authors: Dey
authors: Department of Molecular & Experimental Medicine, Avera Research Institute Sioux Falls, SD ; Department of Internal Medicine, SSOM, University of South Dakota SD.
authors: Brian
authors: B
authors: Leyland-Jones
authors: Department of Molecular & Experimental Medicine, Avera Research Institute Sioux Falls, SD ; Department of Internal Medicine, SSOM, University of South Dakota SD.
authors: Pradip
authors: P
authors: De
keywords: Breast tumors; MYC; PI3K inhibitors; PIK3CA; resistance
references: J Clin Oncol. 2011 Nov 20;29(33):4452-61
references: 22010023
references: Expert Rev Anticancer Ther. 2008 Oct;8(10):1689-98
references: 18925859
references: Cancer Cell. 2010 Jan 19;17(1):77-88
references: 20129249
references: Nature. 2011 Nov 23;480(7377):387-90
references: 22113612
references: Cancer Discov. 2014 Oct;4(10):1154-67
references: 25104330
references: J Cell Biochem. 2012 Jan;113(1):13-8
references: 21898546
references: N Engl J Med. 2012 Feb 9;366(6):520-9
references: 22149876
references: Clin Cancer Res. 2004 Jan 15;10(2):499-507
references: 14760071
references: Genes Dev. 2000 Oct 1;14(19):2501-14
references: 11018017
references: Am J Cancer Res. 2013 Apr 03;3(2):230-9
references: 23593544
references: Adv Cancer Res. 1982;37:1-32
references: 6763842
references: Cancer Res. 2014 Mar 1;74(5):1338-48
references: 24448237
references: Steroids. 2011 Jul;76(8):750-2
references: 21420991
references: Nat Rev Cancer. 2003 Mar;3(3):179-92
references: 12612653
references: Mod Pathol. 2011 Feb;24(2):209-31
references: 21076461
references: Nat Med. 2011 Aug 07;17(9):1116-20
references: 21822287
references: Blood. 2007 Oct 15;110(8):2996-3004
references: 17562874
references: Mol Cell Biol. 2005 Sep;25(17):7917-25
references: 16107734
references: Br J Cancer. 2004 Apr 19;90(8):1612-9
references: 15083194
references: PLoS One. 2013 Oct 15;8(10):e77425
references: 24143235
references: Cancer Discov. 2013 Dec;3(12):1345-54
references: 24265156
references: Cell. 2012 Mar 30;149(1):22-35
references: 22464321
references: Nat Rev Cancer. 2008 Dec;8(12):976-90
references: 19029958
references: BMC Cancer. 2013 Nov 10;13:537
references: 24209998
references: Cancer Cell. 2014 Jul 14;26(1):136-49
references: 25002028
references: Nature. 2010 Aug 12;466(7308):869-73
references: 20668451
references: Clin Cancer Res. 2005 Jun 15;11(12):4321-30
references: 15958613
references: Clin Biochem. 2001 Oct;34(7):557-62
references: 11738392
references: Br J Cancer. 2000 Dec;83(12):1688-95
references: 11104567
references: N Engl J Med. 2002 Aug 15;347(7):472-80
references: 12181401
references: Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):E699-708
references: 21876152
references: Sci Am. 1982 Mar;246(3):80-92
references: 6281879
references: Nat Chem Biol. 2011 Sep 25;7(11):787-93
references: 21946274
references: Mol Cell Biol. 1999 Jan;19(1):1-11
references: 9858526
references: Nat Genet. 1997 Apr;15(4):356-62
references: 9090379
references: N Engl J Med. 2010 Oct 28;363(18):1734-9
references: 20979473
references: Cell. 2000 Jan 7;100(1):57-70
references: 10647931
references: PLoS Comput Biol. 2008 Feb 29;4(2):e1000013
references: 18463697
references: Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10853-8
references: 18664580
references: J Clin Invest. 2007 Aug;117(8):2067-74
references: 17671641
references: Cancer Res. 2009 Sep 15;69(18):7357-65
references: 19706770
references: Cancer Cell. 2010 Nov 16;18(5):459-71
references: 21075311
references: J Clin Oncol. 2006 Jul 20;24(21):3340-6
references: 16785471
references: Cancer Res. 2008 Aug 1;68(15):6084-91
references: 18676830
references: Cancer Treat Rev. 2013 Aug;39(5):403-12
references: 23352077
references: Oncogene. 2010 Nov 18;29(46):6085-98
references: 20818418
references: Cancer Res. 2008 Nov 15;68(22):9221-30
references: 19010894
references: N Engl J Med. 2005 Feb 24;352(8):786-92
references: 15728811
references: Genes Dev. 2006 Aug 1;20(15):2096-109
references: 16847353
references: Nature. 1985 May 16-22;315(6016):239-42
references: 2987699
references: Breast Cancer Res Treat. 2011 Sep;129(2):635-43
references: 21617917
references: Science. 1997 Mar 28;275(5308):1943-7
references: 9072974
references: Clin Cancer Res. 2012 May 1;18(9):2603-12
references: 22407832
references: Sci Signal. 2013 Apr 02;6(269):pl1
references: 23550210
references: Cancer Cell. 2011 Jan 18;19(1):58-71
references: 21215704
references: Cancer Res. 2007 Dec 1;67(23):11209-17
references: 18056446
references: Cancer Cell. 2005 Jun;7(6):561-73
references: 15950905
references: Cancer Res. 2005 Apr 1;65(7):2554-9
references: 15805248
references: Clin Cancer Res. 2007 Dec 15;13(24):7264-70
references: 18094406
references: Cancer Res. 2009 Oct 1;69(19):7491-4
references: 19773439
references: Sci Transl Med. 2013 Jul 31;5(196):196ra99
references: 23903756
references: Cancer Res. 2009 Jan 15;69(2):565-72
references: 19147570
references: Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3698-703
references: 20133671
references: Tumour Biol. 2013 Dec;34(6):3945-58
references: 23860775
references: Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7
references: 18093943
references: Genes Cancer. 2010 Jun;1(6):629-40
references: 21779462
references: Gene. 2006 Jan 17;366(1):2-16
references: 16377102
references: Science. 2004 Apr 23;304(5670):554
references: 15016963
references: Oncogene. 2004 Apr 19;23(18):3217-21
references: 15094771
references: BMC Cell Biol. 2010 Jan 20;11:7
references: 20089194
references: N Engl J Med. 2001 Apr 5;344(14):1038-42
references: 11287973
references: Genes Chromosomes Cancer. 2004 Sep;41(1):1-11
references: 15236312
references: Science. 2007 May 18;316(5827):1039-43
references: 17463250
references: Endocr Relat Cancer. 2000 Sep;7(3):143-64
references: 11021963
references: Nature. 2012 Oct 4;490(7418):61-70
references: 23000897
references: Cancer Cell. 2009 May 5;15(5):429-40
references: 19411071
references: J Clin Invest. 2006 Oct;116(10):2695-706
references: 16906227
references: Sci Signal. 2011 Mar 29;4(166):ra17
references: 21447798
references: Breast Cancer Res. 2011 Mar 01;13(2):R21
references: 21362200
references: Cancer Discov. 2012 May;2(5):401-4
references: 22588877
references: PLoS One. 2008 Aug 20;3(8):e2987
references: 18714337
references: Science. 2001 Aug 3;293(5531):876-80
references: 11423618
references: Oncotarget. 2014 Jul 15;5(13):4581-602
references: 25015035
references: Breast Cancer Res. 2014 Jan 23;16(1):R9
references: 24451154
references: N Engl J Med. 2014 Mar 13;370(11):997-1007
references: 24450857
references: Sci Transl Med. 2011 Mar 23;3(75):75ra26
references: 21430269
references: Science. 2013 Mar 29;339(6127):1546-58
references: 23539594
references: Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11988-93
references: 23803853
references: Leukemia. 2013 Mar;27(3):650-60
references: 23038273
references: Semin Cancer Biol. 2006 Aug;16(4):318-30
references: 16934487
references: Cancer Res. 2008 Oct 1;68(19):8022-30
references: 18829560
references: Cancer Res. 2014 Feb 1;74(3):641-6
references: 24459181
references: Cancer Res. 2006 Feb 1;66(3):1500-8
references: 16452206
references: Clin Cancer Res. 2008 May 15;14(10):2895-9
references: 18483355
references: N Engl J Med. 2009 Sep 3;361(10):947-57
references: 19692680
references: Cancer Res. 2008 Nov 15;68(22):9479-87
references: 19010923
references: Harvey Lect. 1982-1983;78:137-72
references: 6926988
references: Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6
references: 17114293
references: Pigment Cell Melanoma Res. 2012 Nov;25(6):819-31
references: 22883054
references: Br J Haematol. 2010 May;149(4):484-97
references: 20346013
references: Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9262-7
references: 16751266
references: Nat Med. 2004 Aug;10 (8):789-99
references: 15286780
references: Cancer Cell. 2012 Aug 14;22(2):167-79
references: 22897848
references: Int J Mol Med. 2012 Aug;30(2):337-43
references: 22580499
references: Blood. 2013 Apr 11;121(15):2964-74
references: 23403624
references: Mol Cell. 2002 May;9(5):1031-44
references: 12049739
references: Nature. 2007 Jul 26;448(7152):439-44
references: 17611497